<DOC>
	<DOCNO>NCT02716675</DOCNO>
	<brief_summary>This study evaluate safety efficacy human monoclonal antibody ( mAb ) VRC-HIVMAB060-00-AB ( VRC01 ) prevent HIV-1 infection among men transgender ( TG ) person sex men , North America , South America , Switzerland .</brief_summary>
	<brief_title>Evaluating Safety Efficacy VRC01 Antibody Reducing Acquisition HIV-1 Infection Among Men Transgender Persons Who Have Sex With Men</brief_title>
	<detailed_description>This study evaluate safety , tolerability , efficacy VRC01 antibody prevent HIV-1 infection men transgender ( TG ) person sex men , North America , South America , Switzerland . Participants randomize receive VRC01 mAb intravenous ( IV ) infusion dose 10 mg/kg 30 mg/kg every 8 week , receive control infusion every 8 week . All participant receive VRC01 antibody placebo IV infusion Weeks 0 ( study entry ) , 8 , 16 , 24 , 32 , 40 , 48 , 56 , 64 , 72 . For 3 day follow infusion , participant ask record report symptom study researcher . In addition infusion visit , participant attend study visit Weeks 4 , 8 + 5 day , 12 , 20 , 28 , 36 , 44 , 52 , 60 , 68 , 76 , 80 , 84 , 88 , 92 . All study visit include blood collection HIV test counseling . Select study visit include medical history review , physical exam , urine collection , pregnancy test participant capable become pregnant , risk reduction counseling , interview/questionnaire .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>General Demographic Criteria Age 18 50 year Access participate clinical research site ( CRS ) willingness follow plan duration study Ability willingness provide inform consent Assessment understanding : volunteer demonstrate understand study completes questionnaire prior first infusion verbal demonstration understand questionnaire item answer incorrectly Agrees enroll another study investigational research agent duration participant 's trial participation Good general health show medical history , physical exam , screen laboratory test HIVRelated Criteria Willingness receive HIV test result Willingness discuss HIV infection risk amenable HIV risk reduction counsel Persons bear Male identify Transgender ( TG ) ( see HVTN 704/HPTN 085 SSP ) , 6 month prior randomization , experience 1 follow HIV risk criterion : Condomless anal intercourse 1 male transgender partner ( ) Anal intercourse 2 male transgender partner Maletofemale femaletomale TG volunteer eligible . Receipt hormonal therapy make TG volunteer ineligible . Volunteers mutually monogamous relationship HIV1 seronegative partner great 1 year exclude . Laboratory Inclusion Values : Hematology Hemoglobin ( Hgb ) great equal 10.5 g/dL volunteer bear female , great equal 13.0 g/dL volunteer bear male Platelets great equal 100,000 cells/mm^3 Chemistry Alanine aminotransferase ( ALT ) less 2.5 time institutional upper limit normal creatinine less equal 1.25 time institutional upper limit normal Virology HIV uninfected , define SSP , within 30 day prior enrollment Urine Negative , trace , 1+ ( 30 g/L semiquantitative ) urine protein dipstick Reproductive Status Volunteers capable become pregnant : negative serum urine beta human chorionic gonadotropin ( Î²HCG ) pregnancy test perform screen visit prior infusion day initial infusion . Persons NOT capable become pregnant due undergone total hysterectomy bilateral oophorectomy ( verified medical record ) require undergo pregnancy test . Reproductive Status : A volunteer capable become pregnant must agree consistently use effective contraception ( see protocol SSP information ) sexual activity could lead pregnancy least 21 day prior enrollment last require protocol clinic visit . Volunteers capable become pregnant must also agree seek pregnancy alternative method , artificial insemination vitro fertilization last require protocol clinic visit General Investigational research agent receive within 30 day first infusion Body mass index ( BMI ) great equal 40 Pregnant breastfeed Any reactive , indeterminate , positive HIV test , even subsequent test indicate individual HIV infect , except permit HVTN 704/HPTN 085 PSRT . Vaccines HIV vaccine ( ) receive prior HIV vaccine trial . For volunteer receive control/placebo HIV vaccine trial , HVTN 704/HPTN 085 Protocol Safety Review Team ( PSRT ) determine eligibility casebycase basis . Immune System Serious adverse reaction VRC01 formulation component sodium citrate , sodium chloride , Larginine hydrochloride , include history anaphylaxis relate symptom hive , respiratory difficulty , angioedema , and/or abdominal pain . Autoimmune disease , include Type I diabetes mellitus ( Not exclude participation : Volunteer mild , stable uncomplicated autoimmune disease require consistent immunosuppressive medication , judgment site investigator , likely subject exacerbation likely complicate reactogenicity AE assessment ) Immunodeficiency syndrome Clinically Significant Medical Conditions Clinically significant medical condition , physical examination finding , clinically significant abnormal laboratory result , past medical history clinically significant implication current health . A clinically significant condition process include limited : Any contraindication repeat infusion blood draw , include inability establish venous access ; A condition require active medical intervention monitoring avert grave danger volunteer 's health wellbeing study period ; A condition process sign symptom could confuse reaction VRC01 . Any medical , psychiatric , occupational , condition , judgment investigator , would interfere , serve contraindication , protocol adherence , assessment safety infusion reaction , volunteer 's ability give inform consent Psychiatric condition precludes compliance protocol . Specifically excluded person psychosis within past 3 year , ongoing risk suicide , history suicide attempt gesture within past 3 year . Asthma , mild , wellcontrolled asthma Bleeding disorder diagnose doctor ( e.g. , factor deficiency , coagulopathy , platelet disorder require special precaution ) Malignancy ( Not exclude participation : Volunteer malignancy excise surgically , investigator 's estimation , reasonable assurance sustain cure , unlikely experience recurrence malignancy period study ) Seizure disorder : History seizure ( ) within past three year . Also exclude volunteer use medication order prevent treat seizure ( ) time within past 3 year . History hereditary angioedema , acquire angioedema , idiopathic angioedema History organ tissue transplantation Known hepatic renal dysfunction</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV-1 Infections</keyword>
</DOC>